Home  /  Resource Library  /  Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Results of a phase III trial investigating bortezomib combined with standard chemoimmunotherapy for first line treatment of DLBCL. Patients were also stratified by DLBCl subtypes.